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Abstract
Background: The purpose of this study is to evaluate the spectrum of scleritis from database of Ocular
Autoimmune Systemic Inflammatory Infectious Study (OASIS) at a tertiary eye referral eye institute in Singapore.
Clinical records of 120 patients with scleritis from a database of 2200 patients from Ocular Autoimmune Systemic
Inflammatory Infectious Study (OASIS) were reviewed.
Results: 56.6% were females, with a mean age of 48.6 ± 15.9 years. 75 (62.5%) had diffuse anterior scleritis, 25 (20.
8%) had nodular anterior scleritis, 7 (5.8%) had necrotizing anterior scleritis and 13 (10.8%) had posterior scleritis.
Ocular complications were observed in 53.3% of patients, including anterior uveitis (42.5%), raised intraocular
pressure (12.5%), and corneal involvement (11.7%). Autoimmune causes were associated with 31 (25.8%) of patients,
and 10 (8.3%) patients had an associated infective etiology, much higher than Caucasian studies. 53.3% of patients
were treated with oral corticosteroids while 26.7% required immunosuppressives.
Conclusions: Infective etiology needs to be considered in patients of scleritis from Asian origin. In our study and in
OASIS database, scleritis was associated with systemic autoimmune disease and ocular complications.
Keywords: Scleritis, Epidemiology, Complications, Treatment
Background
Scleritis is an uncommon potentially sight threatening
ocular inflammatory disease [1, 2]. It is typically a severe
painful inflammatory process characterized by inflamma-
tion of the sclera associated with engorgement of the
conjunctival, superficial, and deep episcleral vessels.
Based on the Watson and Hayreh classification system
[3], scleritis is divided into anterior and posterior types.
The anterior type is further subdivided into diffuse,
nodular, and necrotizing with or without inflammation.
Ocular complications include scleral and corneal
thinning, perforation, keratitis, anterior uveitis, glau-
coma, cataract, and exudative retinal detachment [1, 3].
Necrotizing scleritis, in particular, has been more fre-
quently associated with ocular complications [3, 4].
The disease may be idiopathic but previous studies
have suggested that scleritis is often associated with, and
may be the first sign of potentially life-threatening sys-
temic autoimmune diseases in 30–50%. The most com-
mon are rheumatoid arthritis, granulomatosis with
polyangiitis (formerly Wegener’s granulomatosis), sero-
negative spondyloarthropathies, relapsing polychondritis,
and systemic lupus erythematosus (SLE) [5–10]. It may
also be associated with infectious causes, previous ocular
surgery, drugs, or malignancies [2, 6, 7].
Management of scleritis involves a multidisciplinary
approach when associated with a systemic disease.
Treatment is in a stepwise manner with non-steroidal
anti-inflammatory drugs (NSAIDs), followed by corticoste-
roids, and subsequently, steroid sparing immunosuppressive
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agents in cases of unsatisfactory therapeutic response or if
prolonged treatment is necessary. Examples of such agents
are azathioprine, cyclosporine, methotrexate, cyclophospha-
mide, and mycophenolate mofetil (MMF) [11–13]. In cases
of refractory or therapy-resistant ocular inflammatory eye
disease, tumor necrosis factor alpha (TNF-α) antagonists
such as infliximab and adalimumab are becoming increas-
ingly used, together with other immunosuppressive agents
[14–20]. More recently, rituximab, a CD20 monoclonal
antibody, has also been described for refractory scleritis [21].
As scleritis is a relatively uncommon disorder, there
are limited large studies documenting clinical experience
with this disease, especially in Asian populations [22–
24]. We aim to analyze our clinical experience with this
disorder, in particular, the associated systemic diseases,
complications, treatments methods, and outcomes of pa-
tients with scleritis presenting to a tertiary institution in
Singapore from a very large database of ocular inflam-
matory disease—Ocular Autoimmune Systemic Inflam-
matory Infectious Study (OASIS) database.
Results
One hundred and twenty patients (5.45%) with scleritis
were identified during this 11-year period, out of a total
of 2200 patients that presented to our Uveitis and Ocu-
lar Inflammation service. The detailed demographic and
clinical characteristics of all patients included in this
study are summarized in Table 1. There were 52 (43.3%)
males and 68 (56.7%) females. The mean age was 48.6 ±
15.9 (range 16–83) years. Eighty three patients (69.2%)
were Chinese, 15 (12.5%) Indian, 14 (11.7%) Malay, and
8 (6.7%) patients of other races. The disease was bilateral
in 37 patients (30.8%). The commonest presenting com-
plaints included eye redness (n = 105, 87.5%), ocular pain
(n = 80, 66.7%), and blurring of vision (n = 21,17.5%).
Diffuse anterior scleritis (n = 75, 62.5%) was the most
common type of scleritis, followed by nodular (n = 25,
20.8%), posterior (n = 13, 10.8%) and necrotizing anterior
scleritis (n = 7, 5.8%). Demographic and clinical charac-
teristics of the subtypes of scleritis are summarized in
Table 2. The mean age at presentation was highest for
necrotizing anterior scleritis (63.7 ± 16.5 years) com-
pared to other forms of scleritis (48.6 ± 14.1 years for
diffuse, 44.0 ± 16.9 for nodular, and 49.2 ± 20.3 for pos-
terior). There were statistically significant differences in
age among the 4 subtypes of scleritis (p = 0.037). Post
hoc pairwise comparisons showed that patients in total
necrotizing subtype were 19.7 years older than patients
in nodular subtype (95% confidence interval (CI) from
1.8 to 37.5, adjusted p = 0.022).
Complications
At least one ocular complication was observed in 53.3%
of all patients either at presentation or at follow up.
Corneal involvement (ulceration, keratitis), high intraoc-
ular pressure, and anterior uveitis constituted major an-
terior segment complications while vitritis, cystoid
macular edema, exudative retinal detachment, and optic
disc swelling were the major posterior segment compli-
cations. Ocular complications were present in 49.3% (n
= 37) of diffuse, 40.0% (n = 10) of nodular, 85.7% (n = 6)
of necrotizing, and 84.6% (n = 11) of posterior scleritis.
Posterior scleritis and necrotizing scleritis were associ-
ated with higher rates of ocular complications (p =
0.014). The most common complication was anterior
uveitis, which occurred in 51 (42.5%) of patients.
Posterior segment complications were most commonly
observed in patients with posterior scleritis (p < 0.001).
This included exudative retinal detachment (RD) (30.8%,
n = 4), cystoid macular edema (23.1%, n = 3), and optic
disc swelling (15.4%, n = 2).
Systemic associations
Associated autoimmune and infective associations are
summarized in Table 3. Autoimmune and infective causes
were associated with 31 (25.8%) and 10 (8.3%) of scleritis
patients, respectively. The most common associated auto-
immune cause was rheumatoid arthritis (7.5%), followed
by granulomatosis with polyangiitis (4.2%), relapsing
polychondritis (3.3%), Sjogren’s syndrome (3.3%), and
psoriatic arthropathy (1.7%). Necrotizing anterior scleritis
had the highest proportion with an autoimmune condition
(85.7%), followed by posterior scleritis (30.8%), and diffuse
scleritis (25.3%), p = 0.001. Only 2 out of 25 (8.0%) patients
with nodular scleritis patients had an associated auto-
immune conditions.
Infective screen was done in 41 patients. The most
commonly associated infective cause was positive test
for latent mycobacterial infection. Ten showed a positive
TB T spot, and 3 were indeterminate. A disproportion-
ately high percentage of nodular scleritis (6 patients out
of 25, or 24%) were associated with a possible infective
cause, while only 8% had an associated autoimmune
cause. Nodular scleritis was found to have a higher asso-
ciation with a probable infective etiology.
Treatment
Treatment modalities for all patients are shown in
Table 4. One hundred and fourteen (95%) were treated
with topical corticosteroids as first-line treatment. Sixty-
three patients (52.5%) were treated oral NSAIDs, 64
(53.3%) patients were treated with oral corticosteroids,
and 26.7% needed immunosuppressants including aza-
thioprine (n = 16, 13.3%), methotrexate (n = 11, 9.2%),
MMF (n = 6, 5%), sulphasalazine (n = 6, 5%), hydroxy-
chloroquine (n = 5, 4.2%), cyclophosphamide (n = 4,
3.3%), and cyclosporine (n = 4, 3.3%). Intravenous meth-
ylprednisolone was given to 5 patients (4.2%), and 2
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patients required biologic agents (intravenous Inflixi-
mab) (1.7%). The choices of oral NSAIDs or systemic
steroids/immunosuppressants were made clinically, de-
pending on the severity of the scleritis.
Among the 100 patients with non-necrotizing (diffuse
and nodular) anterior scleritis, 56 (56.0%) received oral
NSAIDs as first-line therapy, with 96 patients (96.0%)
treated with topical steroids. Out of the 56 patients
receiving NSAID therapy, 41 (41.0%) responded and re-
quired no further treatment. Fifteen patients (15.0%)
were unresponsive to therapy and were given either sys-
temic corticosteroids alone or in combination with im-
munosuppressive drugs. For 31 patients (31.0%), the first
choice treatment was systemic corticosteroids.
Oral corticosteroids were used in 85.7% of necrotizing
anterior scleritis and 92.3% of posterior scleritis, com-
pared to 49.3% of diffuse scleritis and 32% of nodular
scleritis. Around 70% of necrotizing anterior scleritis
and 38.5% of posterior scleritis patients required im-
munosuppressive agents while only 24.0% and 12.0% of
diffuse and nodular scleritis required immunosuppres-
sive treatment.
Anti-tubercular therapy for 6 months was given in the
patients with latent tubercular disease.
Recurrence and resolution
Recurrence of scleritis occurred in 20 patients
(16.7%), with the largest proportion of recurrence
amongst patients with necrotizing anterior scleritis
(n = 2, 26.6%), followed by diffuse anterior scleritis
(n = 14, 18.7%) (p = 0.463).
Resolution of inflammation was longer amongst
patients with necrotizing sclerosis, and occurred in
Table 1 Demographic and clinical characteristics of patients with
scleritis from Ocular Autoimmune Systemic Inflammatory Infectious
Study (OASIS) database
Characteristics No. of patients, n (%)











Ocular complications (any) 64 (53.3%)
Anterior segment
Anterior uveitis 51 (42.5%)
Corneal involvement (ulceration, keratitis) 14 (11.7%)
Ocular hypertension 15 (12.5%)
Posterior segment
Cystoid macular edema 3 (2.5%)
Exudative retinal detachment 5 (4.2%)
Optic disc swelling 3 (2.5%)
Systemic associations
Autoimmune 31 (25.8%)
Rheumatoid arthritis 9 (7.5%)
Granulomatosis with polyangitis 5 (4.2%)
Relapsing polychondritis 4 (3.3%)
Sjogren’s syndrome 4 (3.3%)
Psoriatic arthropathy 2 (1.7%)
Systemic lupus erythematosus 1 (0.8%)
Behcet’s disease 1 (0.8%)
Churg-Strauss syndrome 1 (0.8%)
Ulcerative colitis 1 (0.8%)
Takayasu’s arteritis 1 (0.8%)
Non-specific autoimmune disease 1 (0.8%)
Orbital inflammatory syndrome 1 (0.8%)
Other non-autoimmune systemic: 2 (1.7%)
Myelodysplastic syndrome 1 (0.8%)
Polyclonal gammopathy 1 (0.8%)
Presumed infectious association 10 (8.3%)
TB T-spot positive 5 (4.2%)
Herpes zoster ophthalmicus 2 (1.7%)
Herpes simplex viral keratitis 1 (0.8%)
Acquired immunodeficiency syndrome 1 (0.8%)
Table 1 Demographic and clinical characteristics of patients with
scleritis from Ocular Autoimmune Systemic Inflammatory Infectious
Study (OASIS) database (Continued)
Hansen’s disease 1 (0.8%)
Recurrence 20 (16.7%)
Treatment
Topical steroids 114 (95.0%)
Oral non-steroidal anti-inflammatory drugs 63 (47.3%)
Oral corticosteroids 64 (53.3%)
Systemic immunosuppressant (any) 32 (26.7%)
Azathioprine 16 (13.3%)
Methotrexate 11 (9.2%)




Tumor necrosis factor-α antagonist (infliximab) 2 (1.7%)
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19.3 days in diffuse, 21.2 days in nodular. and 75 days in
necrotizing scleritis.
Discussion
Scleritis is an uncommon inflammatory disease that may
cause complications if not treated in a timely manner.
This retrospective study involved 120 patients with scler-
itis seen over an 11-year period in a tertiary eye center
in Singapore.
The mean age of our patients were 48.6, slightly younger
compared to the Caucasian population (51.5 years) [9].
Our female to male ratio was 1.3:1, similar to the rates
reported in the literature (1.27:1 and 1.57:1) [4, 9, 27].
Around 31% of patients had bilateral disease, similar to
the data reported by Sainz de la Maza et al. (34%) [4].
Laboratory evaluation revealed positive autoimmune
markers in 34 patients (28.3%). Fourteen (11.7%) were RF
positive, 13 (10.8%) were ANA positive, 9 (7.5%) were
ANCA positive, and 3 (2.5%) were anti-dsDNA (DsDNA)
positive. Out of these, three were newly diagnosed with RA,
three granulomatosis with polyangiitis, and one with SLE.
Our results showed that laboratory investigations are useful
in diagnosing an underlying systemic disease associated with
scleritis. Screening for an underlying systemic disease should
be aimed at diseases with higher associations such as RA
and granulomatosis with polyangiitis. As presence of scleritis
is associated with a worse prognosis and a higher mortality
rate in patients with rheumatoid arthritis, initial systemic
evaluation and close follow-up of patients with idiopathic
scleritis and rheumatoid factor positive is crucial [25].
Previous series from North America and Europe have
demonstrated that systemic autoimmune diseases are
present in approximately 30–50% of patients with scler-
itis [3, 4, 26]. In our study, 25.8% had a systemic rheu-
matologic disease. This is similar to other Asian studies
which showed an association in 15–22% of patients
Table 2 Demographic and clinical characteristics of patients classified into subtypes of scleritis (no. of patients, n (%))
Diffuse Nodular Necrotizing Posterior
Number of patients 75 (62.5) 25 (20.8) 7 (5.8) 13 (10.8)
Age (mean) years 48.6 44.0 63.7 49.2
Range 20–74 18–79 38–83 16–80
Gender
Male 32 (42.7) 12 (48.0) 2 (28.6) 5 (38.5)
Female 43 (57.3) 13 (52.0) 5 (71.4) 8 (61.5)
Ocular complications (any) 37 (49.3) 10 (40.0) 6 (85.7) 12 (84.6)
Anterior segment
Corneal involvement (ulceration, keratitis) 7 (9.3) 4 (16.0) 2 (28.6) 1 (7.7)
Ocular hypertension 9 (12.0) 2 (8.0) 2 (28.6) 2 (15.4)
Anterior uveitis 30 (40.0) 8 (32.0) 5 (71.4) 8 (61.5)
Posterior segment
Vitritis 0 0 0 3 (23.1)
Cystoid macular edema 0 0 0 3 (23.1)
Exudative retinal detachment 0 0 1 (14.3) 4 (30.8)
Optic disc swelling 1 (1.3) 0 0 2 (15.4)
Table 3 Associated autoimmune and systemic disease (no. of
patients, n (%))
Diffuse Nodular Necrotizing Posterior
Number of patients 75 (62.5) 25 (20.8) 7 (5.8) 13 (10.8)
Systemic autoimmune
disease
19 (25.3) 2 (8.0) 6 (85.7) 4 (30.8)
Rheumatoid arthritis 6 (5.0) 0 3 (42.9) 0
Granulomatosis with
polyangitis
3 (4.0) 0 0 2 (15.4)
Relapsing polychondritis 2 (2.7) 1 (4.0) 1 (14.3) 0
Psoriatic arthropathy 2 (2.7) 0 0 0
Presumed infectious
association
4 (5.3) 6 (24.0) 0 (0) 0 (0)
Table 4 Treatment and recurrence (no. of patients, n (%))
Diffuse Nodular Necrotizing Posterior
Number of patients 75 (62.5) 25 (20.8) 7 (5.8) 13 (10.8)
Topical steroids 71 (94.7) 25 (100) 6 (85.7) 12 (92.3)
Oral NSAID 40 (53.3) 16 (64.0) 3 (42.9) 4 (30.8)
Oral corticosteroids 37 (49.3) 9 (36.0) 6 (85.7) 12 (92.3)
Oral immunosuppressives
(excluding prednisolone)
19 (25.3) 3 (12.0) 5 (71.4) 5 (38.5)
Oral steroid or
immunosuppressives
40 (53.3) 9 (36.0) 6 (85.7) 12 (92.3)
Recurrence 14 (18.7) 2 (8.0) 2 (28.6) 2 (15.4)
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[24, 27–29]. Our findings similarly suggest that the asso-
ciation with systemic diseases might be lower in Asian
populations with scleritis compared to North American
and European populations [30, 31]. The most common
rheumatologic disease is RA, followed by granulomatosis
with polyangiitis, relapsing polychondritis, Sjogren’s syn-
drome, and psoriatic arthropathy. A comparison of the re-
sults from our study with previously published data (other
Asian, European, and North American studies) are sum-
marized in Table 5.
Associated infective screen was positive in 10 patients
(8.3%), with TB being the most common in our study.
Three of the patients with presumed TB-related nodular
scleritis were foreign nationals working in Singapore
(2 from China, and 1 from India).
Based on current literature, an infectious cause is
found in 4–18% of patients, of which herpes zoster is
the most common, followed by TB, syphilis, leprosy, and
Lyme borreliosis [3, 6, 9, 32]. A study by Tabara [33] has
suggested that TB might be involved in the pathogenesis
of scleritis in some patients, particularly in eyes that
present with localized elevated nodules of the sclera.
Asian patients with nodular scleritis may benefit from
screening for an infective agent such as TB, as they will
require a different therapeutic approach. It is also im-
portant to note that TB is still an important infective
cause in the Asian patient who presents with scleritis.
In addition to autoimmune diseases and infections, it is
also important to bear in mind that a malignancy can be
the underlying disease in a patient with scleritis. Posterior
scleritis has been reported in patients with lymphoma,
multiple myeloma, and Waldenstrom macroglobulinemia
[34]. In our study, there was one patient with myelodys-
plastic syndrome and another with polyclonal gammopa-
thy. Medication, surgery, and trauma are reported to be
rare in all studies.
Management of non-necrotizing anterior scleritis con-
sists of NSAIDs in combination with topical corticoste-
roids as first line based on published data [2, 5, 35, 36].
21% of patients with non-necrotizing anterior scleritis
required additional immunosuppressive agents while
85.7% necrotizing, and 30.8% of posterior scleritis re-
quired immunosuppressive therapy. In the study by Jabs
et al. [8], nearly 67% of patients with scleritis required
more than NSAID therapy, and 26% needed immuno-
suppressant therapy. In our study, we found a similar
treatment pattern with 65.8% of patients needing more
than NSAIDs to control the inflammation, and 25.8%
were treated with immunosuppressive drugs.
TNF-α (infliximab) is a biologic immunomodulatory
agent used as first line for Behcet’s disease or for ocular
complications of rheumatoid arthritis when patients
have failed combination treatment with one or more im-
munosuppressive agents [35] In our series, 2 patients
(1.7%) were started on infliximab treatment. One was
due to necrotizing anterior scleritis secondary to relaps-
ing polychondritis, and another due to nodular scleritis
secondary to rheumatoid arthritis. Both failed treatment
with corticosteroids, azathioprine, cyclosporine, and my-
cophenolate mofetil. In general, for this study, intraven-
ous infliximab were used only after failure of several
different types of immunosuppressive agents in a step
ladder increment, due to financial factors as insurance
does not cover the costs of these new agents locally.
Resolution of inflammation occurred in 19.3 days in
diffuse, 21.2 days in nodular, and 75 days in necrotizing
scleritis. In the study by Tuft and Watson [9], patients
with diffuse scleritis received treatment for the shortest
period, whereas the mean duration of treatment was
longest for the necrotizing group. This finding is consist-
ent with our study which showed that resolution of in-
flammation is shortest in diffuse and longest in
necrotizing scleritis. Recurrence rate is highest among
the necrotizing scleritis, with 28.6% of patients having at
least 1 recurrence.
The limitations of our study lie mainly in the retrospect-
ive nature, with a relatively small sample size collected
from a single institution. This may not fully reflect the
spectrum of scleritis of our entire local population. Fur-
thermore, the treatment modalities may differ depending
on the preferences of the ocular inflammation specialists.
Nonetheless, this is a relatively uncommon condition, and
our data was obtained over a long 11-year period. The re-
sults of our study add to the knowledge of the epidemi-
ology of scleritis in an Asian clinical setting.
Conclusions
In conclusion, scleritis is a severe ocular inflammation
which may be idiopathic, or associated with autoimmune
or infectious cause. While infectious causes are uncom-
mon, Asian patients with nodular scleritis may need
screening for an infective agent such as TB as this may
alter the management of this disease. Treatment may in-
volve a step ladder management strategy with oral
Table 5 Comparison of the results from our series with















25.8 15–22 32.7–52 35.8–39
Infectious
cause (TB)
4.2 7.2 0 0–2
Systemic steroid
therapy
53.3 42.2 61.5 31.9–36.7
Immunosuppressive
therapy
26.7 22.9 34–36 26.1–38.0
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NSAIDs, oral corticosteroids, and immunosuppressants/
biologic agents. Close monitoring of complications, es-
pecially for necrotizing scleritis and posterior scleritis,
systemic evaluation, and timely treatment are necessary
for these patients.
Methods
We retrospectively analyzed the case records of all con-
secutive new scleritis cases diagnosed at the Uveitis and
Ocular Inflammation service of our hospital, from Janu-
ary 2004 to December 2014 from 2200 patients in the
OASIS database.
Data collected included information such as age at diag-
nosis, race, gender, anatomic location of inflammation,
presenting complaints, ocular complications, associated
systemic or inflammatory disease, investigations, use of
topical and/or systemic treatments, and recurrence.
The diagnosis of scleritis was based on a comprehen-
sive clinical history including a systemic review, detailed
ocular examination, and investigations when deemed ne-
cessary. The Watson system was used to classify the type
of scleritis [3], with the diagnosis of posterior scleritis
confirmed by ultrasonography and/or CT of the orbit
[34]. In all the cases, the diagnosis of scleritis was made
by a uveitis specialist in our ocular inflammation service.
Complications were divided into anterior and posterior
segment complications. Corneal complications included
ulcerative or peripheral thinning, while anterior uveitis was
diagnosed when 1+ cells (based on the Standardization of
Uveitis Nomenclature Working Group Criteria) [37] or
more were observed in the anterior chamber. Ocular hyper-
tension was defined as an intraocular pressure of more than
21 mmHg measured by the Goldmann applanation tonom-
eter (GAT). The presence of cystoid macular edema was
noted clinically and confirmed by further investigations
such as optical coherence tomography or fundus fluores-
cein angiography. Serous retinal detachment was diagnosed
on fundoscopy or ultrasound.
Laboratory testing included blood tests, urine tests,
and a chest radiograph. Blood tests included a complete
blood count (CBC) and white cell differential, acute
phase reactants such as erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP), liver and renal func-
tion tests. Autoimmune markers such as rheumatoid
factor (RF), anti-nuclear antibodies (ANA), anti-double-
stranded DNA (anti-dsDNA), anti-neutrophil cytoplas-
mic antibody (ANCA) were also included. Other tests,
which include infective screening for tuberculosis (TB)
using the tuberculosis interferon gamma release assay
(T-SPOT.TB, Oxford Immunotec, UK), treponemal
serology (syphilis IgG and Venereal Disease Research
Laboratory (VDRL)), were not taken routinely, but when
deemed necessary based on history and physical
examination. A history of scleritis with discharge, or
associated trauma, and examination findings of a yellow-
ish nodular lesion was deemed more suspicious for an in-
fective cause and further investigations were performed.
Associated systemic diseases were classified into infec-
tious or autoimmune. These were diagnosed based on
the results of a compatible history, clinical features, and
laboratory data, often in conjunction with rheumatolo-
gists and infectious disease physicians.
Treatment involved oral NSAIDs, topical, and/or sys-
temic corticosteroids depending on the severity, location,
and chronicity of the inflammatory process, as well as
the risk of visual loss and complications. Immunosup-
pressive drugs were used as a second-line therapy when
there was failure of response to oral corticosteroid
monotherapy, development of intolerable side effects to
corticosteroids, or in the presence of associated systemic
rheumatological disease.
Recurrence was defined as repeated episodes of scler-
itis separated by periods of inactivity over 3 months in
duration without treatment. The duration of follow-up
was also obtained.
All data were entered into a computerized database
system for descriptive analysis and analyzed with IBM
SPSS Statistics software (version 22, IBM, New York,
USA) and R (version 3.1.2, The R Foundation for
Statistical Computing), with continuous variables
expressed as mean with standard deviation, and range
and categorical variables as percentages. Pearson’s chi-
square test was performed to analyze association be-
tween the groups of patients and their demographics
and clinical characteristics. If expected counts within
a category were less than 5 for more than 20% of
cells, Fisher’s exact test was used instead. Age among
the groups of patients were compared using one way
analysis of variance (ANOVA), and post hoc pairwise
comparisons done with Bonferroni correction applied
if the ANOVA showed results of statistical signifi-
cance. A p value of <0.05 was considered to indicate
statistical significance.
The study was approved by the National Healthcare
Group Domain Specific Review Board, the conduct of
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